Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Coronavirus: Brazil to use Chinese vaccine

Federal government has agreed to buy 46 million doses of CoronaVac, says Sao Paulo governor

Rory Sullivan
Wednesday 21 October 2020 12:47 BST
Comments
Workers are pictured on 24 September, 2020, at a packaging facility owned by Sinovac, the company that is developing the CoronaVac vaccine.
Workers are pictured on 24 September, 2020, at a packaging facility owned by Sinovac, the company that is developing the CoronaVac vaccine. (REUTERS)

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

Brazil intends to use a coronavirus vaccine developed in China as part of its national immunisation scheme, state officials have said.

The announcement about the Chinese-made “CoronaVac” vaccine came after state governors met with Brazil’s health minister on Tuesday.

The country of 230 million people has agreed to buy 46 million doses of it from the Chinese biopharmaceutical company Sinovac, according to Joao Doria, the governor of Sao Paulo.

If it gains regulatory approval, CoronaVac will become one of two vaccines used in Brazil’s inoculation programme against the virus - the other being the one currently under development by the University of Oxford and AstraZeneca in the UK.

The Butantan Institute, a research centre in the state of Sao Paulo which is running a large-scale trial of CoronaVac with 9,000 volunteers, said on Monday that the vaccine was safe. 

Although preliminary, it was the first result to come out of any of Sinovac’s global late-phase trials, which are also taking place in Indonesia and Turkey.

Dimas Covas, the director of the Butantan Institute, added that details about CoronaVac’s effectiveness would not be made public until the trial ended.

The Sao Paulo government has already asked health regulators to approve the vaccine for use, with Mr Doria saying the country could possibly roll out mass vaccinations from as early as January next year. 

Brazil has been badly affected by Covid-19 and has so far recorded 5,273,954 and 154,837 deaths from the virus, according to data from Johns Hopkins University.

Only the US has had more Covid-19 deaths than Brazil, with 220,171. 

Additional reporting by Reuters

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in